Understand the source comparison
NAD+ Help Chronic Fatigue Research: Precursor Comparison
Nicotinamide Riboside (NR) NRK → NMN → NAD+ 500–1000mg daily Skeletal muscle, liver, brain (moderate) Good. Minimal GI side effects at ≤1000mg Most consistent clinical evidence for systemic NAD+ elevation; best-tolerated at therapeutic doses Nicotinamide Monon
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Nicotinamide Riboside (NR)
- NRK → NMN → NAD+
- 500–1000mg daily
- Skeletal muscle, liver, brain (moderate)
- Good. Minimal GI side effects at ≤1000mg
- Most consistent clinical evidence for systemic NAD+ elevation; best-tolerated at therapeutic doses
- Nicotinamide Mononucleotide (NMN)
- Direct → NAD+ (contested) or → NAM → NAD+
- 250–500mg daily
- Uncertain. May require extracellular conversion to NR
- Moderate. Nausea/bloating common above 300mg
- Promising mechanistic rationale but weaker human bioavailability data than NR; unclear if intact NMN crosses membranes
- Nicotinamide (NAM)
- NAMPT → NAD+
- 500–1500mg daily
- Ubiquitous (all tissues)
- Poor. Flushing, nausea above 1000mg
- Saturates NAMPT at high doses, limiting NAD+ synthesis; inferior to NR/NMN for targeted mitochondrial support
- Nicotinic Acid (Niacin)
- Preiss-Handler pathway → NAD+
- 100–500mg daily
- Liver-preferential
- Very poor. Intense flushing (prostaglandin-mediated)
- Effective for hepatic NAD+ but intolerable side effects make it impractical for chronic use